Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Erdafitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 known ✓ | P11362 | 20/20 | 1.00 |
| ▸ | FGFR2 known ✓ | P21802 | 20/20 | 1.00 |
| ▸ | FGFR3 known ✓ | P22607 | 20/20 | 1.00 |
| ▸ | FGFR4 known ✓ | P22455 | 18/20 | 1.00 |
| ▸ | KDR | P35968 | 18/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 1/20 | 1.00 |
| ▸ | ETV6 | P41212 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 10/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Erdafitinib SCHEMBL29359988 | 1.00 | FGFR1 (1.00) | FGFR1FGFR2FGFR3FGFR4KDR | |
| Erdafitinib SCHEMBL17979118 | 0.99 | FGFR3 (1.00) | FGFR1FGFR2FGFR3FGFR4KDR | |
| Erdafitinib SCHEMBL16642100 | 0.97 | FGFR1 (1.00) | FGFR1FGFR2FGFR3FGFR4KDR | |
| SCHEMBL22907838 | 0.95 | FGFR3 (0.90) | FGFR1FGFR2FGFR3FGFR4KDR | |
| SCHEMBL12178368 | 0.95 | FGFR1 (1.00) | FGFR1FGFR2FGFR3FGFR4KDR | |
| SCHEMBL14788610 | 0.94 | FGFR1 (0.89) | FGFR1FGFR2FGFR3FGFR4KDR | |
| SCHEMBL14788629 | 0.94 | FGFR1 (0.89) | FGFR1FGFR2FGFR3FGFR4KDR | |
| SCHEMBL12178550 | 0.94 | FGFR1 (1.00) | FGFR1FGFR2FGFR3FGFR4KDR | |
| SCHEMBL12179046 | 0.94 | FGFR3 (1.00) | FGFR1FGFR2FGFR3FGFR4KDR | |
| Erdafitinib SCHEMBL16642098 | 0.94 | FGFR3 (1.00) | FGFR1FGFR2FGFR3FGFR4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3162 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| US-20260140118-A1 | COMBINATION DRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-05-21 | — | — | US | claimed |
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | NANOTECH PHARMA INC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4741395-A1 | NOVEL COMPOUND SENSITIVE TO NITROGEN MONOXIDE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Omniamed Co. Ltd (KR) | 2026-05-13 | — | — | EP | claimed |
| WO-2026090174-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOF | BRYET US, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4731199-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING COLORECTAL CANCER | Burzynski, Stanislaw R. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4731792-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING LUNG CANCER | Burzynski, Stanislaw R. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4731793-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING PANCREATIC CANCER | Burzynski, Stanislaw R. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4727534-A1 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING BREAST CANCER | Burzynski, Stanislaw R. (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4727596-A2 | ANTIBODY-DRUG CONJUGATES AND LINKERS AND METHODS OF USE THEREOF | Ohio State Innovation Foundation (US) | 2026-04-22 | — | — | EP | claimed |
| EP-3122358-A1 | COMBINATIONS | Astex Therapeutics Ltd. (GB) | 2017-02-01 | — | — | EP | claimed |
| EP-2563775-B1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2017-01-04 | — | — | EP | claimed |
| US-20160311800-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2016-10-27 | — | — | US | claimed |
| US-9464071-B2 | Pyrazolyl quinoxaline kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2016-10-11 | — | — | US | claimed |
| WO-2016128411-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING N-(3,5-DIMETHOXYPHENYL)-N'-(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANE-1,2-DIAMINE | ASTEX THERAPEUTICS LIMITED (GB) | 2016-08-18 | — | — | WO | claimed |
| WO-2015144808-A1 | COMBINATIONS OF AN FGFR INHIBITOR AND AN IGF1R INHIBITOR | ASTEX THERAPEUTICS LTD (GB) | 2015-10-01 | — | — | WO | claimed |
| WO-2015144804-A1 | COMBINATIONS | ASTEX THERAPEUTICS LTD (GB) | 2015-10-01 | — | — | WO | claimed |
| US-20150105368-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2015-04-16 | — | — | US | claimed |
| US-8895601-B2 | Pyrazolyl quinoxaline kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2014-11-25 | — | — | US | claimed |
| US-20130072457-A1 | PYRAZOLYL QUINAZOLINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2013-03-21 | — | — | US | claimed |